HIV infection
Conditions
Interventions
Patient Screener consists of five questions answered by PLWH. It is completed by the PLWH before the clinical consultation and is used by healthcare professionals to identify individuals who may be el
Sponsors
International University of Health and Welfare
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Part I. Implementation of a Patient Screener and shared Decision-Making Guide PLWH: 1.Over 18 years old 2.Agree to complete the Part I surveys 3.Virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months 4.Without present or past evidence of viral resistance to either CAB or RPV, and with no prior virological failure 5.Serologically negative for hepatitis B surface antigen 6.Not pregnant 7.Not breastfeeding 8.Must not use medicines contraindicated to CAB+RPV LA and oral CAB+RPV HCPs: 1.Either a physician, nurse, or pharmacist working at the study sites 2.Agree to complete the Part I surveys Part II. Implementation of CAB+RPV LA PLWH: 1.Over 18 years old 2.Completed Part I of the study 3.Agree to complete the Part II survey and interview at M8 4.Will switch to CAB+RPV LA as part of their routine clinical care 5.Virologically suppressed (HIV- 1 RNA <50 copies/mL) for at least 6 months on ART 6.Without present or past evidence of viral resistance to either CAB or RPV, and with no prior virological failure 7.Serologically negative for HBs antigen 8.Not pregnant 9.Not breastfeeding 10.Must not use medicines contraindicated to CAB+RPV LA and oral CAB+RPV HCPs: 1.Either a physician, nurse, or pharmacist working at the study sites 2.Have at least one patient that switched to CAB+RPV LA following use of the shared Decisions Making Tool and Patient Screener 3.Agree to complete the survey and interview
Exclusion criteria
Exclusion criteria: Individuals who meet any of the following criteria will be excluded from this study. PLWH and HCPs: 1.Cognitively impaired 2.Unable to speak, read, and write in Japanese 3.Critically ill subjects 4.Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result or the participant's ability to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the utility of a Patient Screener and Shared Decision-Making Guide and the acceptability of CAB+RPV LA in PLWH and HCPs. | — |
Countries
Japan
Contacts
Public ContactJunko Tanuma
International University of Health and Welfare Department of Infectious Diseases
Outcome results
None listed